Group 1 - The core viewpoint of the report is that Xianruida Medical-B (06669) is given a "strong buy" investment rating due to its innovative capabilities and product strength, supported by the global platform of its controlling shareholder, Boston Scientific, which enhances performance certainty through collaboration in overseas expansion and new product development [1] Group 2 - Xianruida is a leading domestic company focused on providing comprehensive vascular intervention solutions, having launched the first knee and below DCB products in China, and is positioned at the forefront of the peripheral intervention field [1][2] Group 3 - The company has established a multi-technology platform since 2011, developing drug-coated balloon (DCB) and percutaneous transluminal angioplasty (PTA) products, achieving a comprehensive layout in the peripheral intervention field with over 30 listed products by H1 2025, covering vascular surgery, cardiology, nephrology, and neurology [2] Group 4 - The product lineup is structured in a "pyramid" model, with mature products like DCB and PTA balloons being the main revenue source, while growth products such as peripheral suction systems and radiofrequency ablation systems are expected to drive future revenue growth [3] Group 5 - A new three-year cooperation agreement was signed with Boston Scientific for 2026-2028, which includes global commercialization, product manufacturing, and R&D support, with projected sales to Boston Scientific reaching up to $30 million, $62 million, and $78 million in the respective years [4]

Core Viewpoint - The report from China Merchants Securities initiates coverage on Xianruida Medical-B (06669) with a "strong buy" rating, highlighting the company's innovative capabilities and product strength, as well as the performance certainty brought by the collaboration with its controlling shareholder, Boston Scientific, in overseas expansion and new product development [1]. Company Overview - Xianruida is a leading domestic innovative medical device platform focused on providing comprehensive vascular intervention solutions, having launched the first knee and below DCB products in China, and is positioned at the forefront of the peripheral intervention field [2]. Technology and Product Development - The company has been engaged in the R&D of PTA and DCB products since 2011, establishing a multi-technology platform that includes drug-coated technology, radiofrequency ablation technology, polymer material technology, and aspiration platform technology, achieving a comprehensive layout in vascular intervention with over 30 listed products by H1 2025, covering vascular surgery, cardiology, nephrology, and neurology [3]. Product Portfolio and Growth - The company has built a "pyramid" product group since the launch of its core knee DCB product in China in 2016, leading to steady revenue growth: 1. Mature products, including DCB and PTA balloons, are the main revenue sources, with the company holding the top market share in the domestic peripheral DCB sector and securing multiple procurement bids [4]. 2. Growth-stage products, such as peripheral aspiration systems and radiofrequency ablation systems, are in early volume expansion and are expected to contribute significantly to future revenue growth [4]. 3. The pipeline includes in-development projects like lower limb rapamycin DCB and IVL systems, covering mainstream departments and serving as a core source for medium to long-term growth [4]. Collaboration with Boston Scientific - In February 2023, Boston Scientific became the controlling shareholder of Xianruida with a 65% stake and signed a memorandum of understanding in June 2023. A new three-year cooperation agreement was signed for 2026-2028, which includes: 1. Global commercialization, sharing Boston Scientific's global channel resources, with projected sales to Boston Scientific capped at $30 million, $62 million, and $78 million for 2026, 2027, and 2028 respectively [5]. 2. Product manufacturing, providing OEM services with projected transaction amounts of $1 million, $1 million, and $3 million for the same years [5]. 3. Product R&D, with mutual support and CSO services [5].

Core Viewpoint - Xianruida is a leading domestic innovative medical device platform focused on providing comprehensive vascular intervention solutions, having launched the first knee and below DCB products in China, and is positioned at the forefront of the peripheral intervention field [1] Group 1: Product Development and Market Position - The company has established a multi-technology platform since 2011, developing PTA and DCB products, and has over 30 listed products as of H1 2025, covering vascular surgery, cardiology, nephrology, and neurology [1] - The product lineup includes mature products like DCB and PTA balloons, which are the main revenue sources, with the company holding the number one market share in the domestic peripheral DCB sector [2] - Growth-stage products such as peripheral suction systems and radiofrequency ablation systems are expected to drive future revenue growth due to their early-stage market penetration [2] Group 2: Strategic Partnerships and Future Outlook - In February 2023, Boston Scientific became the controlling shareholder of Xianruida, holding 65%, and a new three-year cooperation agreement was signed in December 2025, focusing on global commercialization, manufacturing services, and R&D collaboration [3] - The agreement includes projected sales to Boston Scientific of up to $30 million, $62 million, and $78 million from 2026 to 2028, and manufacturing service transactions of up to $1 million, $1 million, and $3 million in the same period [3] - The company is expected to achieve net profits of 120 million, 220 million, and 320 million yuan from 2025 to 2027, with year-on-year growth rates of 137.7%, 73.3%, and 49.7%, respectively, and a strong investment recommendation is given based on its innovative capabilities and strategic partnerships [3]

Core Viewpoint - The company reported strong mid-year performance for 2025, with significant revenue and profit growth driven by its neurovascular and peripheral vascular intervention products [1][2]. Group 1: Financial Performance - The company achieved operating revenue of 482 million yuan, an increase of 31.7% year-on-year [1] - Gross profit reached 343 million yuan, up 31.5%, with a gross margin of 71.2%, slightly down by 0.1 percentage points [1] - Unadjusted profit was 121 million yuan, a 76.0% increase, while adjusted profit was 131 million yuan, up 68.1% [1] - Cash on hand amounted to 2.53 billion yuan [1] Group 2: Product Performance - Neurovascular intervention products generated revenue of 305 million yuan, accounting for 63.3% of total revenue, with a growth of 25.0% [1] - Peripheral vascular intervention products saw revenue of 177 million yuan, a 46.2% increase, raising their revenue share to 36.6% [1] Group 3: Cost Management - The company improved operational efficiency, with sales and distribution expense ratio at 17.7%, down 4.2 percentage points [1] - Research and development expense ratio was 25.2%, down 2.5 percentage points [1] - Administrative expense ratio stood at 11.6%, down 0.3 percentage points [1] Group 4: Market Opportunities - The company has seen significant success in centralized procurement, with notable wins in various product categories [2] - The global neurointerventional market is valued at approximately 7 billion USD, with China accounting for 15%-20% [2] - The global peripheral intervention market is around 10 billion USD, with China representing 12%-15% [2] - The company has a diverse product matrix, with 73 products approved or in development, and 22 products commercialized in 27 countries [2] Group 5: International Expansion - The company is expanding its international business, particularly in Europe and emerging markets like Brazil, India, and South Africa [2] - Overseas sales revenue reached 15.72 million yuan, a year-on-year increase of 36.8% [2]